Theriva Biologics, Inc. (TOVX) income statement
TOVXNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$0.13−0.02 (-11.11%)
Close on Nov 19, 2026Market cap $5.87MP/E –Yield –
Theriva Biologics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 1.13
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 93.6%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?